Citations

Clear

2 citation(s) found for "Silva, Rita".

Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study
Cari, Vania , Pérez, María Ignacia , Tellez, Ignacio , Idalsoaga, Francisco, Valsan, Arun , Nair, Gowripriya , Soni, Kriti , Rhoads, S. Fisher , Arnold, Jorge , Ayala-Valverde, Maria, Ramirez-Cadiz, Carolina, Jalal, Prasun K., Ibrahim, Mohamad Ali , Elfeki, Mohamed A., Simian, Daniela , Córdova, Jacqueline, Higuera‐de‐la‐Tijera, Fátima , Silva, Rita, Rocha, Cristina Melo , Araujo, Roberta C., Fontani, Guilherme Massote, Pereira, Gustavo Henrique, Bessone, Fernando, Tanno, Mario, Kisch, Ayelen, Mendizabal, Manual, Marciano, Sebastian, Gomez-Perdiguero, Gonzalo, Montes, Pedro, Salazar, Patricia Guerra, Ramos, Geraldine, Chacko, Kristina R., Skladaný, Lubomir, Maiwall, Rakhi, SIMONETTO, DOUGLAS, Sanyal, A, Shah, Vijay H. , Singal, Ashwani K., Dunn, Winston, Kamath, Patrick S., Loomba, R, Arrese, Marco, Bataller, Ramon, Diaz, Luis Antonio, Arab, Juan Pablo, Elfeki, Mohamed A. , Perez, María I , Idalsoaga, Francisco , Ayala-Valverde, María , Ramirez-Cadiz, Carolina , Jalal, Prasun K , Ibrahim, Mohamad A , Elfeki, Mohamed A , Roblero, Juan P , Simian, Daniela , Velarde-Ruiz Velasco, José Antonio , Cordova-Gallardo, Jacqueline , Higuera-De La Tijera, Fatima , Silva, Rita , Fontani, Guilherme M , Bessone, Fernando , Mendizabal, Manuel , Marciano, Sebastián , Gomez-Perdiguero, Gonzalo , Montes, Pedro , Guerra Salazar, Patricia , Chacko, Kristina R , Simonetto, Douglas A , Sanyal, A J , Singal, Ashwani K , Dunn, Winston , Kamath, Patrick S , Loomba, Rohit , Bataller, Ramon A , Díaz, Luis A , Gormaz, Vania Cari, Téllez, Ignacio García, Idalsoaga, Francisco , Rhoads, Fisher, Ayala-Valverde, María , Jalal, Prasun K. , Roblero, Juan Pablo , Velasco, J.A. Velarde-Ruiz , Araújo, Roberta Chaves , Massote, Guilherme Fontanini, Pereira, Gustavo , Chacko, Kristina R. , Maiwall, Rakhi , Simonetto, Douglas A. , Sanyal, Arun J. , Singal, Ashwani K. , Dunn, Winston , Kamath, Patrick S. , Loomba, Rohit , Arrese, Marco , Díaz, Luis Antonio , Arab, Juan Pablo

Mayo Clinic

Hepatology | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001780 | PMID 42090455 Get It

Introduction: Although the role of cardiometabolic risk factors (CMRF) has been characterized in steatotic liver disease, their role in the severity of alcohol-associated hepatitis (AH) remains unclear. We aimed to evaluate the impact of CMRF on mortality. Methods: Multinational prospective cohort study (2015–2024) including hospitalized patients with severe AH across 32 centers in 14 countries. Diagnosis of AH was made using the NIAAA criteria. Analyses included adjusted competing-risk models by age, sex, ethnicity, history of cirrhosis, CMRF, corticosteroid use, MELD, and ACLF grade, with liver transplantation as a competing risk. Results: 936 participants were included; mean age 48±11.2 years, and 88.9% were male. At least one CMRF was present in 46.6%; median body mass index (BMI) was 24.2 kg/m 2 [IQR: 22.8–28.2], prevalence of diabetes 17.6%, hypertension 16.5%, and dyslipidemia 5.8%. Median MELD was 24.4 [19.3–31.4], 86.7% had severe AH, and 180-day survival was 72.9%. Survival did not differ by CMRF status (log-rank p =0.453). In adjusted competing-risk models, higher age (sHR 1.02; 95%CI:1.01–1.04), greater alcohol intake (per g/day; sHR 1.001; 95%CI:1.000–1.002), MELD (sHR 1.04; 95%CI:1.01–1.06), and ACLF grade 2–3 (sHR 2.34 and 4.34) predicted mortality. However, no individual CMRF independently increased mortality. A prespecified non-linear BMI analysis showed modestly lower mortality between 25–40 kg/m², with a higher risk above 40 kg/m². Conclusion: Among patients with severe AH, metabolic dysfunction was not associated with increased mortality. Although a higher BMI was associated with slightly lower mortality in AH, this may reflect better nutritional status rather than a true protective effect.
Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL
Rutten, Julie W. , Cerfontaine, Minne N. , Hack, Remco J. , Jolly, Amy A. , Guey, Stéphanie , Hsu, Shao‐Lun , Yuan, Yun , Neilson, S. , Poggesi, Anna, Shourav, Md Manjurul Islam , Ishiyama, Hiroyuki , Mayoral, Ana Domínguez, Nogueira, Renata , Muiño, Elena , Santo, Gustavo, Sukhonpanich, Nontapat , Park, Ashley , Lee, Jung Seok , Rodríguez-Girondo, Mar , Vonk, Sebastiaan J. J., Börjesson‐Hanson, Anne, Pantoni, Leonardo , Montanaro, Vinícus V. A., Kalaria, Raj N. , Pescini, Francesca , Choi, Jay Chol , Chen, Ling , Kim, Hyunjin , Markus, Hugh , Lee, Yi‐Chung , Oberstein, Saskia A.J. Lesnik , Guey, Stéphanie , Neilson, Sam J , Shourav, Md Manjurul Islam , Lee, Yi-Chung , Lesnik Oberstein, Saskia A J , Rutten, Julie W , Gravesteijn, Gido , Liao, Yi‐Chu , Park, Jae Young , Kopczak, Anna , Rifino, Nicola , Poggesi, Anna , Saitô, Satoshi , Andersen, Pia, Stefano, Nicola De , Santo, Gustavo, Mele, Francesco , Brodtmann, Amy G. , Fernández‐Cadenas, Israel , Silva, Ana Rita , Montanaro, Vinícius Viana Abreu , Lopergolo, Diego , Ihara, Masafumi , Meschia, James F. , Muir, Keith W. , Bersano, Anna , Duering, Marco , Chabriat, Hugues

Mayo Clinic

JAMA Neurology | November 29, 2024 | Volume: 82 | Issue: 1 | Pages: 49

10.1001/jamaneurol.2024.4487 | PMID 39610302 Get It

Importance Typical cysteine-altering NOTCH3 ( NOTCH3 cys ) variants are highly prevalent (approximately 1 in 300 individuals) and are associated with a broad spectrum of small vessel disease (SVD), ranging from early-onset stroke and dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]) to nonpenetrance. A staging system that captures the full NOTCH3 -SVD severity spectrum is needed and currently lacking. Objective To design a simple disease severity staging system that captures the broad clinicoradiological NOTCH3 -SVD severity spectrum. Design, Setting, and Participants A cohort study was performed in which the NOTCH3 -SVD severity staging system was developed using a discovery cohort (2019-2020) and validated in independent international CADASIL cohorts (1999-2023) and the UK Biobank. Clinical and imaging data were collected from participants originating from 23 international CADASIL cohorts and from the UK Biobank. Eligibility criteria were presence of a NOTCH3 cys variant, availability of brain magnetic resonance imaging, and modified Rankin Scale score. The discovery cohort consisted of 195 NOTCH3 cys -positive cases from families with CADASIL; the validation set included 1713 NOTCH3 cys -positive cases from 15 countries. The UK Biobank cohort consisted of 101 NOTCH3 cys -positive individuals. Data from 2-year (2019-2023) and 18-year (1999-2017) follow-up studies were also analyzed. Data analysis was performed from July 2023 to August 2024. Main Outcomes and Measures Percentage of cases following the sequence of events of the NOTCH3 -SVD stages, and the association between the stages and ischemic stroke, intracerebral hemorrhage, global cognition, processing speed, brain volume, brain microstructural damage, and serum neurofilament light chain (NfL) level. Results The NOTCH3 -SVD staging system encompasses 9 disease stages or substages, ranging from stage 0 (premanifest stage) to stage 4B (end stage). Of all 1908 cases, which included 195 in the discovery cohort (mean [SD] age, 52.4 [12.2] years) and 1713 in the validation cohorts (mean [SD] age, 53.1 [13.0] years), 1789 (94%) followed the sequence of events defined by the NOTCH3 -SVD staging system. The NOTCH3 -SVD stages were associated with neuroimaging outcomes in the NOTCH3 cys -positive cases in the CADASIL cohorts and in the UK Biobank and with cognitive outcomes and serum NfL level in cases from the CADASIL cohorts. The NOTCH3 -SVD staging system captured disease progression and was associated with 18-year survival. Conclusions and Relevance The NOTCH3 -SVD staging system captures the full disease spectrum, from asymptomatic individuals with a NOTCH3 cys variant to patients with end-stage disease. The NOTCH3 -SVD staging system is a simple but effective tool for uniform disease staging in the clinic and in research.